Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Recursion Pharmaceuticals Inc’s stock clocked out at $7.28, down -1.75% from its previous closing price of $7.41. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 3.55 million shares were traded. RXRX stock price reached its highest trading level at $7.5964 during the session, while it also had its lowest trading level at $7.195.
Ratios:
To gain a deeper understanding of RXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.07 and its Current Ratio is at 6.07. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 29 ’24 when Marriott Tina bought 6,000 shares for $7.56 per share.
Borgeson Blake sold 11,447 shares of RXRX for $81,532 on Aug 20 ’24. The Director now owns 7,132,769 shares after completing the transaction at $7.12 per share. On Aug 20 ’24, another insider, Borgeson Blake, who serves as the Director of the company, bought 11,447 shares for $7.12 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2054692864 and an Enterprise Value of 1660984064. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.40 while its Price-to-Book (P/B) ratio in mrq is 3.50. Its current Enterprise Value per Revenue stands at 33.464 whereas that against EBITDA is -4.551.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $4.97. The 50-Day Moving Average of the stock is -4.37%, while the 200-Day Moving Average is calculated to be -19.76%.
Shares Statistics:
It appears that RXRX traded 5.56M shares on average per day over the past three months and 4352210 shares per day over the past ten days. A total of 226.26M shares are outstanding, with a floating share count of 215.42M. Insiders hold about 23.67% of the company’s shares, while institutions hold 77.35% stake in the company. Shares short for RXRX as of 1723680000 were 54147202 with a Short Ratio of 9.75, compared to 1721001600 on 49327170. Therefore, it implies a Short% of Shares Outstanding of 54147202 and a Short% of Float of 26.75.
